MAKO Surgical Corp (MAKO) Peer Comparison
$10.79
$-0.13
(-1.19%)
As on 27-Aug-2026 13:32EDT
Market cap
$923 Mln
Revenue (TTM)
$208 Mln
P/E Ratio
17.9
P/B Ratio
4.8
Div. Yield
0 %
Edit
| MAKO Surgical Corp (MAKO) | Lineage, Inc. (LINE) | Viamet Pharmaceuticals Corp (VMET) | Republic Airways Holdings Inc (RJET) | Curanex Pharmaceuticals Inc (CURX) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
923 | 10,434 | 1,155 | 878 | 7 |
Revenue ($ Mln) |
208 | 5,371 | 73 | 1,653 | -- |
Net Profit ($ Mln) |
52.16 | -169.00 | 36.72 | 48.98 | -10.47 |
Net Margin (%) |
25.13 | -3.15 | 50.13 | 2.96 | -- |
RoE (%) |
30.61 | -1.85 | 11.69 | 3.61 | -130.80 |
Price to Earnings |
17.86 | -- | 29.47 | 12.25 | -- |
Price-To-Book |
4.83 | 1.20 | 2.89 | 0.63 | 1.73 |
Income Statement ($ Mln)
| MAKO Surgical Corp (MAKO) | Lineage, Inc. (LINE) | Viamet Pharmaceuticals Corp (VMET) | Republic Airways Holdings Inc (RJET) | Curanex Pharmaceuticals Inc (CURX) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
207.57 | 5,371.00 | 73.25 | 1,653.28 | 0.00 |
|
Cost of Revenue
|
99.94 | 4,782.00 | 33.19 | 1,215.66 | 0.02 |
|
Gross Profit
|
75.02 | 826.00 | 13.48 | 466.00 | -- |
|
Operating Expenses
|
23.17 | 319.00 | 11.50 | 269.36 | 10.52 |
|
Operating Profit (EBIT)
|
84.46 | 270.00 | 28.55 | 168.25 | -10.55 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
83.59 | -189.00 | 52.29 | 86.32 | -10.47 |
|
Provision for Tax
|
31.44 | 0.00 | 15.57 | 37.34 | 0.00 |
|
Profit after Tax (Net Income)
|
52.16 | -169.00 | 36.72 | 48.98 | -10.47 |
|
Minority Interest
|
0.00 | 20.00 | 0.00 | 0.00 | 0.00 |
|
Consolidated Profit
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities ($ Mln)
| MAKO Surgical Corp (MAKO) | Lineage, Inc. (LINE) | Viamet Pharmaceuticals Corp (VMET) | Republic Airways Holdings Inc (RJET) | Curanex Pharmaceuticals Inc (CURX) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
190.04 | 7,893.00 | 394.08 | 1,386.30 | 4.79 |
|
Minority Interest
|
0.00 | 20.00 | 0.00 | 0.00 | 0.00 |
|
Non-Current Liabilities
|
55.77 | 8,436.00 | 340.68 | 1,349.70 | 0.18 |
|
Current Liabilities
|
50.34 | 1,590.00 | 52.51 | 520.40 | 0.10 |
|
Total Liabilities
|
208.45 | 19,185.00 | 418.01 | 3,276.60 | 11.58 |
Assets ($ Mln)
| MAKO Surgical Corp (MAKO) | Lineage, Inc. (LINE) | Viamet Pharmaceuticals Corp (VMET) | Republic Airways Holdings Inc (RJET) | Curanex Pharmaceuticals Inc (CURX) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
139.74 | 17,659.00 | 750.06 | 2,721.30 | 0.28 |
|
Current Assets
|
156.41 | 1,241.00 | 37.20 | 535.10 | 4.79 |
|
Total Assets
|
208.45 | 19,185.00 | 418.01 | 3,276.60 | 11.58 |
|
Total Debt*
|
41.69 | 7,991.00 | 374.55 | 1,194.50 | 0.28 |
|
Net Current Assets
|
0.00 | -349.00 | 0.00 | 14.70 | 0.00 |
Cashflow ($ Mln)
| MAKO Surgical Corp (MAKO) | Lineage, Inc. (LINE) | Viamet Pharmaceuticals Corp (VMET) | Republic Airways Holdings Inc (RJET) | Curanex Pharmaceuticals Inc (CURX) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
52.98 | 943.00 | 16.95 | 322.00 | -10.48 |
|
Cash Flow from Investing Activities
|
-20.34 | -1,067.00 | -159.46 | -350.90 | -- |
|
Cash from Financing Activities
|
30.07 | 14.00 | 144.84 | 54.70 | 15.31 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| MAKO Surgical Corp (MAKO) | Lineage, Inc. (LINE) | Viamet Pharmaceuticals Corp (VMET) | Republic Airways Holdings Inc (RJET) | Curanex Pharmaceuticals Inc (CURX) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
29.00 | -0.60 | 6.94 | 3.17 | -70.02 |
|
ROE (%)
|
30.61 | -1.85 | 11.69 | 3.61 | -130.80 |
|
ROA (%)
|
17.02 | -0.82 | 6.71 | 2.40 | -195.12 |
|
EBIT Margin (%)
|
41.30 | 7.97 | 71.08 | 9.67 | -- |
|
Net Margin (%)
|
25.13 | -3.15 | 50.13 | 2.96 | -- |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | -- | -- |
Growth Ratios
| MAKO Surgical Corp (MAKO) | Lineage, Inc. (LINE) | Viamet Pharmaceuticals Corp (VMET) | Republic Airways Holdings Inc (RJET) | Curanex Pharmaceuticals Inc (CURX) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
0.61 | 1.03 | 1.89 | 134.15 | -- |
|
EBIT Growth (%)
|
-- | 216.94 | -- | 200.33 | -1,445.30 |
|
Net Profit Growth (%)
|
76.17 | 69.93 | 930.56 | 155.09 | -2,306.33 |
|
EPS Growth (%)
|
0.56 | 71.97 | 22.18 | 88.62 | -49,008.41 |
|
Book Value Growth (%)
|
77.13 | -8.21 | -38.33 | 302.10 | 30,570.34 |
Valuation Ratios
| MAKO Surgical Corp (MAKO) | Lineage, Inc. (LINE) | Viamet Pharmaceuticals Corp (VMET) | Republic Airways Holdings Inc (RJET) | Curanex Pharmaceuticals Inc (CURX) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
15.37 | -81.43 | -- | 10.27 | -0.10 |
|
Price / Book Value
|
3.44 | 0.97 | -- | 0.59 | 0.04 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
6.90 | 15.81 | -- | 5.70 | 1.00 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| MAKO Surgical Corp (MAKO) | Lineage, Inc. (LINE) | Viamet Pharmaceuticals Corp (VMET) | Republic Airways Holdings Inc (RJET) | Curanex Pharmaceuticals Inc (CURX) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.79 | 0.00 | 0.63 | 0.00 |
|
Short term debt to equity ratio
|
0.07 | 0.00 | 0.13 | 0.15 | 0.02 |
|
Current Ratio
|
3.11 | 0.78 | 0.71 | 1.03 | 45.95 |
|
Quick Ratio
|
2.35 | 0.70 | 0.71 | 0.84 | 45.95 |
|
Interest Coverage
|
109.90 | 0.70 | 4.83 | 2.65 | -493.63 |
Operating Efficiency Ratios
| MAKO Surgical Corp (MAKO) | Lineage, Inc. (LINE) | Viamet Pharmaceuticals Corp (VMET) | Republic Airways Holdings Inc (RJET) | Curanex Pharmaceuticals Inc (CURX) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
0.55 | 17.13 | 14.16 | 4.14 | -- |
|
Asset Turnover
|
0.68 | 0.26 | 0.13 | 0.81 | 0.00 |
|
Receivable days
|
2.99 | 58.73 | 52.53 | 17.21 | -- |
|
Inventory Days
|
100.11 | 13.39 | -- | 22.86 | -- |
|
Payable days
|
59.08 | 93.39 | 35.28 | 27.62 | -- |
|
Cash Conversion Cycle
|
44.01 | -21.28 | -- | 12.44 | -- |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
